Apnimed Stock Forecast
NASDAQ: APMDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:41 PM ET
APMD analyst consensus
Consensus (4 analysts)
none
Avg. price target
$50.33+172.64%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Apnimed (2026-10-08), 4 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $50.33, with a high estimate of $60.00 and a low estimate of $41.00. The average target implies upside of 172.6% from the current price of $18.46.
The spread between the highest and lowest targets is 46.3%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for APMD.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 4 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $41.00 | +122.10% |
| Average target | $50.33 | +172.64% |
| High target | $60.00 | +225.03% |